78.7%

19.7% 19.0%

32.3%

16.7%

48.3%

24.7%

32.7%

48.3%

4.7% 6.0% 3.0%

18.0%

42.3%

77.3%

13.3% 11.3%

19.3%

0.0%

11.3%

0.0%

14.7%

18.7%

6.7% 6.0% 5.3%

12.0%

22.0%

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

70.0%

80.0%

90.0%

Method:

•In a cross-sectional, open, multicentre pilot validation study we report data from the use of the KPPQ

•Acceptability, stability, convergent validity and agreement with the KPPS were tested.

•Test-retest reliability (stability) was tested after two weeks (average) in 50 patients

• Correlations of the KPPQ with motor features, other non-motor symptoms, and quality of life were also explored. RESULTS:

•300 PD patients and 150 age and gender matched controls with otherwise unexplained pain were assesses (demographics, see table 1) •In PD patients all assessed types of pain were present. Prevalence of the reported types of pain by patients and controls is shown in the graph. •Generalised whole body and abdominal pain, dystonic, RLS related, nocturnal and radicular pain were significantly more prevalent in PD compared to controls (p<0.05, chi-square test). Dyskinetic and “off” related pain were not assessed in controls. •All analysed clinimetric attributes resulted satisfactorily (see table 2). Therefore, the KPPQ can be considered valid and useful.

RESULTS:

Multicentre validation of the first patient completed tool for pain in PD: The King’s Parkinson’s Disease Pain Questionnaire (King’s PD Pain Quest)

Alexandra M Rizos1, Pablo Martinez-Martin2, Suvankar Pal3, Rani Sophia4, Camille Carroll5, Davide Martino6, Cristian Falup-Pecurariu7, Belinda Kessel8, Thomasin Andrews9, Dominic Paviour10, Anna Sauerbier1,11, Anne Martin1, Miriam Parry12, Lauren Perkins1, Dhaval Trivedi1, Theresa Chiwera1, Mubasher

A Qamar1, Per Odin13, Angelo Antonini14, K Ray Chaudhuri, DSc1,11,12 on behalf of EUROPAR & MDS Non-Motor PD Study Group 1Neurology, King’s College Hospital, London, UK; 2National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain; 3Neurology, Forth Valley Royal hospital, Scotland, UK; 4Geriatric Medicine, Yeovil Hospital,

Somerset, UK; 5Neurology, Derriford Hospial, Plymouth, UK; 6Neurology, Queen Mary Hospital, Kent, UK; 7Neurology, Transylvania University, Brasov, Romania; 8Medicine for the Elderly, Princess Royal University Hospital site, King’s College Hospital, Kent, UK; 9Neurology, Guy’s Hospital, London, UK; 10Neurology, St Georges’s Hospital, London, UK; 11Neurology, King’s College, London, UK; 12Neurology, University Hospital Lewisham, London, UK;

13Neurology, University of Lund, Lund, Sweden; 14Neurology, University of Padua, Venice, Italy.

BACKGROUND:

• Pain is an under-explored and poorly characterised non-motor symptom of PD and a major determinant of quality of life2

• The validated King’s PD Pain Scale1 was developed to characterise the various types of pain in PD and to allow for focussed treatment.

• To our knowledge, there is no PD-specific patient completed tool available to empower patients to self-declare pain related symptoms.

OBJECTIVE: To validate an “easy to use” self-completed Parkinson’s specific pain questionnaire using internationally accepted methods: The King’s PD Pain Quest (KPPQ), which is complementary to the validated King’s PD Pain Scale1.

CONCLUSION: These results suggest that the King’s PD Pain Quest is a valid and reliable self-

completed tool complementary to the KPPS for the assessment of patient-reported pain in PD. ACKNOWLEGMENTS: This poster presents independent research funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors of this poster have nothing to declare concerning this poster.

Table 1: Demographics Patients Controls

Number 300 150

Male gender: number (%) 179 (59.7%) 90 (60.0%)

Age (yrs)* 64.9 ± 10.5 (29–88) 64.9 ± 10.2 (29-89)

Education (yrs)* 14.1 ± 4.0 (0-24) 14.4 ± 3.9 (0-25)

Duration of Disease (yrs)* 5.2 ± 4.8 n/a

Hoehn & Yahr Stage: median (range) 2.0 (1.0 – 5.0) n/a

Levodopa equivalent daily dose (mg)* 588.0±464.3 (0-2620) n/a

Patients

Controls

p < 0.05

BACKGROUND: METHODS:

REFERENCES: 1Ray Chaudhuri K. et al., Mov Diso. 2015;30 (12):1623-1631 2Wasner G, Deuschl G., Nat Rev Neurol.2012;17(8):284–294

Graph: Types of pain as measured by the KPPQ

OBJECTIVE:

Table 2 Item Measure Result

Quality of Data, acceptability

Computable data 100% Excellent

Range (total score) Min - Max 1-12

Stability: Intraclass correlation coefficient(ICC) TS

All Items (except item 5 [0.44]) (k) 0.65–1.00 Excellent

Test-retest reliability (ICC) 0.98 Excellent

Agreement KPPS-KPPQuest

11 items (k) 0.61–0.86 Substantial

Items 6.Dystonic, 7.“Off” related, and 13.Burning limb pain (k)

0.50 –0.60 Moderate

Number of pain symptoms captured KPPS–KPPQ (ICC)

0.88 Very high

Convergent Validity with other measures of pain*

KPPQ TS with KPPS TS 0.80 High

KPPQ TS with PDQ-8, item 8 0.46 Moderate

Correlation with PD-related variables*

KPPQ TS with SCOPA motor TS 0.42 Moderate

KPPQ TS with NMSS TS 0.47 Moderate

KPPQ TS with CISI-PD TS 0.37 Moderate

Correlation with other measures*

KPPQ TS with HADS - Anxiety 0.45 High

KPPQ TS with HADS - Depression 0.43 Moderate

KPPQ TS with PDSS TS 0.57 High

KPPQ TS with EQ-5D TS -0.45 Moderate

KPPQ TS with PDQ8 TS 0.56 High

TS=Total Score; KPPQ=King’s PD Pain Quest; KPPS=Kings’ PD Pain Scale; *Spearman rank correlation coefficient (rS)

Endorsed by

Biomedical Research Centre and Dementia Unit at

South London and Maudsley NHS Foundation

Trust and the Institute of Psychiatry, Psychology

and Neuroscience King’s College London

*N/A

*N/A